Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Patterns of hospital utilization after elective minimally invasive foregut surgery.

Jalilvand AD, McNally M, Belle P, Perry KA.

Surg Endosc. 2019 Jul 12. doi: 10.1007/s00464-019-06953-1. [Epub ahead of print]

PMID:
31300909
2.

High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma.

Taylor LA, Abraham RM, Tahirovic E, van Belle P, Li B, Huang L, Elder DE, Gimotty P, Xu X.

Mod Pathol. 2017 May;30(5):634-639. doi: 10.1038/modpathol.2016.226. Epub 2017 Jan 20.

3.

Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

Leroux-Roels G, Marchant A, Levy J, Van Damme P, Schwarz TF, Horsmans Y, Jilg W, Kremsner PG, Haelterman E, Clément F, Gabor JJ, Esen M, Hens A, Carletti I, Fissette L, Tavares Da Silva F, Burny W, Janssens M, Moris P, Didierlaurent AM, Van Der Most R, Garçon N, Van Belle P, Van Mechelen M.

Clin Immunol. 2016 Aug;169:16-27. doi: 10.1016/j.clim.2016.05.007. Epub 2016 May 25.

4.

Uranium from German Nuclear Power Projects of the 1940s--A Nuclear Forensic Investigation.

Mayer K, Wallenius M, Lützenkirchen K, Horta J, Nicholl A, Rasmussen G, van Belle P, Varga Z, Buda R, Erdmann N, Kratz JV, Trautmann N, Fifield LK, Tims SG, Fröhlich MB, Steier P.

Angew Chem Int Ed Engl. 2015 Nov 2;54(45):13452-6. doi: 10.1002/anie.201504874. Epub 2015 Sep 7.

5.

Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.

Levy J, Licini L, Haelterman E, Moris P, Lestrate P, Damaso S, Van Belle P, Boutriau D.

Hum Vaccin Immunother. 2015;11(3):620-31. doi: 10.1080/21645515.2015.1011021.

6.

Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.

Leroux-Roels G, Van Belle P, Vandepapeliere P, Horsmans Y, Janssens M, Carletti I, Garçon N, Wettendorff M, Van Mechelen M.

Vaccine. 2015 Feb 18;33(8):1084-91. doi: 10.1016/j.vaccine.2014.10.078. Epub 2014 Nov 7.

7.

Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Pauksens K, Nilsson AC, Caubet M, Pascal TG, Van Belle P, Poolman JT, Vandepapelière PG, Verlant V, Vink PE.

Clin Vaccine Immunol. 2014 May;21(5):651-60. doi: 10.1128/CVI.00807-13. Epub 2014 Mar 5.

8.

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.

Leroux-Roels I, Devaster JM, Leroux-Roels G, Verlant V, Henckaerts I, Moris P, Hermand P, Van Belle P, Poolman JT, Vandepapelière P, Horsmans Y.

Vaccine. 2015 Jan 15;33(4):577-84. doi: 10.1016/j.vaccine.2013.10.052. Epub 2013 Oct 29.

9.

A variant in FTO shows association with melanoma risk not due to BMI.

Iles MM, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, Harland M, Macgregor S, Taylor JC, Aben KK, Akslen LA, Avril MF, Azizi E, Bakker B, Benediktsdottir KR, Bergman W, Scarrà GB, Brown KM, Calista D, Chaudru V, Fargnoli MC, Cust AE, Demenais F, de Waal AC, Dębniak T, Elder DE, Friedman E, Galan P, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Helsing P, Hočevar M, Höiom V, Hopper JL, Ingvar C, Janssen M, Jenkins MA, Kanetsky PA, Kiemeney LA, Lang J, Lathrop GM, Leachman S, Lee JE, Lubiński J, Mackie RM, Mann GJ, Martin NG, Mayordomo JI, Molven A, Mulder S, Nagore E, Novaković S, Okamoto I, Olafsson JH, Olsson H, Pehamberger H, Peris K, Grasa MP, Planelles D, Puig S, Puig-Butille JA, Randerson-Moor J, Requena C, Rivoltini L, Rodolfo M, Santinami M, Sigurgeirsson B, Snowden H, Song F, Sulem P, Thorisdottir K, Tuominen R, Van Belle P, van der Stoep N, van Rossum MM, Wei Q, Wendt J, Zelenika D, Zhang M, Landi MT, Thorleifsson G, Bishop DT, Amos CI, Hayward NK, Stefansson K, Bishop JA, Barrett JH; GenoMEL Consortium; Q-MEGA and AMFS Investigators.

Nat Genet. 2013 Apr;45(4):428-32, 432e1. doi: 10.1038/ng.2571. Epub 2013 Mar 3.

10.

Genome-wide association study identifies three new melanoma susceptibility loci.

Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF, Andresen PA, Akslen LA, Armstrong BK, Avril MF, Azizi E, Bakker B, Bergman W, Bianchi-Scarrà G, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Corda E, Cust AE, Dębniak T, Duffy D, Dunning AM, Easton DF, Friedman E, Galan P, Ghiorzo P, Giles GG, Hansson J, Hocevar M, Höiom V, Hopper JL, Ingvar C, Janssen B, Jenkins MA, Jönsson G, Kefford RF, Landi G, Landi MT, Lang J, Lubiński J, Mackie R, Malvehy J, Martin NG, Molven A, Montgomery GW, van Nieuwpoort FA, Novakovic S, Olsson H, Pastorino L, Puig S, Puig-Butille JA, Randerson-Moor J, Snowden H, Tuominen R, Van Belle P, van der Stoep N, Whiteman DC, Zelenika D, Han J, Fang S, Lee JE, Wei Q, Lathrop GM, Gillanders EM, Brown KM, Goldstein AM, Kanetsky PA, Mann GJ, Macgregor S, Elder DE, Amos CI, Hayward NK, Gruis NA, Demenais F, Bishop JA, Bishop DT; GenoMEL Consortium.

Nat Genet. 2011 Oct 9;43(11):1108-13. doi: 10.1038/ng.959.

11.

High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma.

Yun SJ, Gimotty PA, Hwang WT, Dawson P, Van Belle P, Elder DE, Elenitsas R, Schuchter L, Zhang PJ, Guerry D, Xu X.

Am J Surg Pathol. 2011 Feb;35(2):235-42. doi: 10.1097/PAS.0b013e3182036ccd.

12.

Experimental re-evaluation of the γ-ray energy and emission probability for the 159 keV transition in 238U following the α-decay of 242Pu.

Berlizov AN, van Belle P, Zuleger E, Ottmar H.

Appl Radiat Isot. 2011 Feb;69(2):531-8. doi: 10.1016/j.apradiso.2010.11.017. Epub 2010 Nov 26.

PMID:
21144759
13.

Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.

Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, Avril MF, Azizi E, van Belle P, Bergman W, Bianchi-Scarrà G, Bressac-de Paillerets B, Calista D, Carrera C, Hansson J, Harland M, Hogg D, Höiom V, Holland EA, Ingvar C, Landi MT, Lang JM, Mackie RM, Mann GJ, Ming ME, Njauw CJ, Olsson H, Palmer J, Pastorino L, Puig S, Randerson-Moor J, Stark M, Tsao H, Tucker MA, van der Velden P, Yang XR, Gruis N; Melanoma Genetics Consortium.

J Natl Cancer Inst. 2010 Oct 20;102(20):1568-83. doi: 10.1093/jnci/djq363. Epub 2010 Sep 28.

14.

Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.

Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM.

J Infect Dis. 2009 Dec 15;200(12):1861-9. doi: 10.1086/648406.

PMID:
19909082
15.

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X.

Am J Pathol. 2009 Jun;174(6):2367-77. doi: 10.2353/ajpath.2009.081057. Epub 2009 Apr 23.

16.

Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial.

Beran J, Ambrozaitis A, Laiskonis A, Mickuviene N, Bacart P, Calozet Y, Demanet E, Heijmans S, Van Belle P, Weber F, Salamand C.

BMC Med. 2009 Apr 2;7:13. doi: 10.1186/1741-7015-7-13.

17.

Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example.

Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, Jirincova H, Van Belle P, Jain V, Innis B, Devaster JM.

BMC Infect Dis. 2009 Jan 17;9:2. doi: 10.1186/1471-2334-9-2.

18.

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.

Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M.

Oncogene. 2009 Jan 8;28(1):85-94. doi: 10.1038/onc.2008.362. Epub 2008 Sep 15.

19.

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL.

Mol Cancer Ther. 2008 Sep;7(9):2876-83. doi: 10.1158/1535-7163.MCT-08-0431.

20.

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, Van Belle PA, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ.

Clin Cancer Res. 2008 Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123.

21.

Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis.

Xu X, Gimotty PA, Guerry D, Karakousis G, Van Belle P, Liang H, Montone K, Pasha T, Ming ME, Acs G, Feldman M, Barth S, Hammond R, Elenitsas R, Zhang PJ, Elder DE.

Hum Pathol. 2008 Jun;39(6):901-9. doi: 10.1016/j.humpath.2007.10.017. Epub 2008 Apr 28.

22.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G.

Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14.

PMID:
18272264
23.

Shared MHC class II-dependent melanoma ribosomal protein L8 identified by phage display.

Swoboda RK, Somasundaram R, Caputo L, Ochoa EM, Gimotty PA, Marincola FM, Van Belle P, Barth S, Elder D, Guerry D, Czerniecki B, Schuchter L, Vonderheide RH, Herlyn D.

Cancer Res. 2007 Apr 15;67(8):3555-9.

24.

Differentiation of normal skin and melanoma using high resolution hyperspectral imaging.

Dicker DT, Lerner J, Van Belle P, Barth SF, Guerry D 4th, Herlyn M, Elder DE, El-Deiry WS.

Cancer Biol Ther. 2006 Aug;5(8):1033-8. Epub 2006 Aug 9.

PMID:
16931902
25.

Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-cell migration toward melanoma cells.

Zhang T, Somasundaram R, Berking C, Caputo L, Van Belle P, Elder D, Czerniecki B, Hotz S, Schuchter L, Spitz FR, Berencsi K, Rani P, Marincola F, Qiu R, Herlyn D.

Cancer Biol Ther. 2006 Oct;5(10):1304-12. Epub 2006 Oct 4.

PMID:
16929176
26.

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, van Belle P, Hotz S, Elder DE, Marincola FM, Schuchter L, Guerry D, Czerniecki BJ, Herlyn D.

Cancer Res. 2006 Mar 15;66(6):3287-93.

27.

Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma.

Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D.

J Clin Oncol. 2005 Nov 1;23(31):8048-56.

PMID:
16258103
28.

A tumorigenic subpopulation with stem cell properties in melanomas.

Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M.

Cancer Res. 2005 Oct 15;65(20):9328-37.

29.

Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder DE, Herlyn M.

Cancer Res. 2003 Feb 15;63(4):756-9.

30.

A versatile method for the removal of melanin from ribonucleic acids in melanocytic cells.

Satyamoorthy K, Li G, Van Belle PA, Elder DE, Herlyn M.

Melanoma Res. 2002 Oct;12(5):449-52.

PMID:
12394186
31.

Isolation of the melanoma-associated antigen p23 using antibody phage display.

Li J, Pereira S, Van Belle P, Tsui P, Elder D, Speicher D, Deen K, Linnenbach A, Somasundaram R, Swoboda R, Herlyn D.

J Immunol. 2001 Jan 1;166(1):432-8.

32.
33.

Human melanoma progression in skin reconstructs : biological significance of bFGF.

Meier F, Nesbit M, Hsu MY, Martin B, Van Belle P, Elder DE, Schaumburg-Lever G, Garbe C, Walz TM, Donatien P, Crombleholme TM, Herlyn M.

Am J Pathol. 2000 Jan;156(1):193-200.

34.

Progression-related expression of beta3 integrin in melanomas and nevi.

Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D 4th, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, Elder DE.

Hum Pathol. 1999 May;30(5):562-7.

PMID:
10333228
35.

Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.

Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M.

Am J Pathol. 1998 Nov;153(5):1435-42.

36.

Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.

Montone KT, van Belle P, Elenitsas R, Elder DE.

Mod Pathol. 1997 Sep;10(9):939-44.

PMID:
9310959
37.

A model system for detection and isolation of a tumor cell surface antigen using antibody phage display.

Pereira S, Maruyama H, Siegel D, Van Belle P, Elder D, Curtis P, Herlyn D.

J Immunol Methods. 1997 Apr 11;203(1):11-24.

PMID:
9134026
38.

Combinatorial antibodies against human malignant melanoma.

Pereira S, Van Belle P, Elder D, Maruyama H, Jacob L, Sivanandham M, Wallack M, Siegel D, Herlyn D.

Hybridoma. 1997 Feb;16(1):11-6.

PMID:
9085122
39.

Neoplastic progression and prognosis in melanoma.

Elder DE, Van Belle P, Elenitsas R, Halpern A, Guerry D.

Semin Cutan Med Surg. 1996 Dec;15(4):336-48. Review.

PMID:
9069601
40.

Melanoma-associated expression of transforming growth factor-beta isoforms.

Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE.

Am J Pathol. 1996 Jun;148(6):1887-94.

41.

Simvastatin and proteinuria.

La Belle P, Mantel G.

Lancet. 1991 Apr 6;337(8745):864. No abstract available.

PMID:
1672961
42.

Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.

Goldberg R, La Belle P, Zupkis R, Ronca P.

Am J Cardiol. 1990 Sep 18;66(8):16B-21B.

PMID:
2206032
43.

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome.

Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendörfer A, Keane WF.

Am J Kidney Dis. 1990 Jan;15(1):8-15.

PMID:
2294737

Supplemental Content

Support Center